TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04861558
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of 460 mg/m2
Study: NCT05929885
Drug: Low Dose OXIRI (LD-OXIRI)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The LD-OXIRI regimen will be administered in the following sequence:~* metronomic capecitabine (Xeloda; X) 650mg/m2 will administered twice a day on a daily a continuous basis;~* intravenous metronomic oxaliplatin (O) 50 mg/m2 will be infused over 120 minutes on days 1 and 8 of a 21 day-cycle; followed by~* intravenous irinotecan (I) will be infused over 90 minutes on days 1 and 8 of a 21 day-cycle. The dose of irinotecan will be based on the particular patient's UGT1A1\*6 and UGT1A1\*28 genotype status.
Study: NCT05897112
Drug: Group A received cryotherpay
Normalized name: meningococcal group A polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group A (DB13889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
Study: NCT05897112
Drug: Group B received 10% Potassium Hydroxide Solution
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
Study: NCT06517862
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonates will receive oral UDCA solution at 10 mg/day given as 5 mg twice daily.
Study: NCT04950205
Drug: Sevoflurane inhalant product
Normalized name: sevoflurane Inhalant Product
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol plus 1% sevoflurane after open Carotid artery until the end of surgery
Study: NCT06048367
Drug: CNSI-Fe(II) 30 mg
Normalized name: Slow-Fe
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned \[based on Fe(II)\]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
Study: NCT06048367
Drug: CNSI-Fe(II) 60 mg
Normalized name: Slow-Fe
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned \[based on Fe(II)\]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
Study: NCT06048367
Drug: CNSI-Fe(II) 90 mg
Normalized name: Slow-Fe
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned \[based on Fe(II)\]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
Study: NCT06391944
Drug: JMT101 Injection
Normalized name: Jmt101 (fully human monoclonal igg1 antibody targeting epidermal growth factor receptor (egfr))
DrugBank: Becotatug (DB19069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 or 21 days
Study: NCT06391944
Drug: Osimertinib tablet
Normalized name: Osimertinib Tablets
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib 80 or 160mg po everyday
Study: NCT00002392
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05010629
Drug: 9-ING-41
Normalized name: ING-1
DrugBank: ING-1 (DB05831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05010629
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion
Study: NCT04715048
Drug: Onabotulinum toxin A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Glabellar line correction
Study: NCT05344027
Drug: Mitotane
Normalized name: Mitotane
DrugBank: Mitotane (DB00648)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individuals within the intervention group were on mitotane therapy as part of their ACC treatment.
Study: NCT05024747
Drug: NicoDerm CQ (Alza)
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single patch of a NicoDerm CQ (Alza) 21 mg/system of 22 cm\^2 surface area will be placed topically.
Study: NCT05663242
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
Study: NCT05663242
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
Study: NCT05978687
Drug: Xylocaine with Epinephrine
Normalized name: Xylocaine with Epinephrine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In group B, all patients will receive a subconjunctival injection with xylocaine 2% hydrochloride solution with 0.125 epinephrine will be injected with a 27-gauge needle. When asked for, patients will receive additional topical 1% lidocaine eye drops.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon.
Study: NCT06281405
Drug: PD-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 antibody (Toripalimab): 240mg d1 q3w
Study: NCT06356948
Drug: Tranexamic Acid (TXA)
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug administration
Study: NCT04702048
Drug: Aflibercept Injection
Normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients randomized to Arm A will receive 2 mg IVT aflibercept injections every 4 weeks (Q4W) to Week 20, followed by 2-mg aflibercept injections Q8W to Week 52.
Study: NCT04702048
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to Arm B will receive sham intravitreal injections every 4 weeks (Q4W) to Week 20, followed by sham intravitreal injections Q8W to Week 52. Sham means eye will be numbed and a syringe with no needle will be touched to the eye.
Study: NCT04796428
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Canagliflozin If the patient is already on metformin, the fixed combination Canagliflozin / Metformin can be used.
Study: NCT04796428
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin If the patient is already on metformin, the fixed combination dapagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination dapagliflozin / saxagliptin can be used.
Study: NCT04796428
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: If the patient is already on metformin, the fixed combination empagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination empagliflozin / linagliptin can be used.
Study: NCT06278896
Drug: Cessation of antibiotics
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stop antibiotic therapy after episode of fever if afebrile for 48 hours, no clinically documented source of bacterial infection, and no hemodynamic or respiratory decompensation.
Study: NCT05675098
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This medication is a psychostimulant medication and is usually prescribed for individuals with Attention-Deficit/Hyperactivity Disorder to manage ADHD behavioral symptoms
Study: NCT05693090
Drug: Tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05693090
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration
Study: NCT05843812
Drug: Magnesium Sulfate 10 MG/ML
Normalized name: magnesium sulfate 10 MG/ML
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who received preoperative infusion with magnesium sulfate as part of their anesthetic management
Study: NCT05137730
Drug: rhPTH(1-84)
Normalized name: rhPTH(1-84)
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.
Study: NCT05675098
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This medication is a Central Nervous System stimulant and is usually used to treat neurological conditions, including Narcolepsy
Study: NCT05363670
Drug: ARS-1
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARS-1
Study: NCT05363670
Drug: Albuterol MDI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mcg
Study: NCT04861948
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT04861948
Drug: Cisplatin/Carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous
Study: NCT04861948
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous
Study: NCT04861948
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT04861948
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous
Study: NCT03003195
Drug: P10s-PADRE
Normalized name: gamma4 heavy chain Homo sapiens (1-442) [VH (Homo sapiens IGHV3-23*04 (94.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.8] (26-33.51-58.97-104)) (1-115)-Homo sapiens IGHG4*01, G4v5 h P10, nG4m(a) CH2 L92 (CH1(116-213), hinge 1-12 S10>P (223) (214-225), CH2
DrugBank: Mevonlerbart (DB19416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection for a total of 4 vaccinations.
Study: NCT05053126
Drug: Pregabalin 300mg
Normalized name: PREGABALIN 300MG CAP,ORAL
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participant will receive an oral dose of pregabalin 300 mg
Study: NCT05053126
Drug: pregabalin 450 mg
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participant will receive an oral dose of pregabalin 450 mg
Study: NCT05053126
Drug: Pregabalin 300 mg with oxycodone 20 mg
Normalized name: pregabalin 300 MG
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participant will receive an oral dose of pregabalin 300 mg and oxycodone 20 mg
Study: NCT05053126
Drug: pregabalin 450 mg with oxycodone 20 mg
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participant will receive an oral dose of pregabalin 450 mg and oxycodone 20 mg
Study: NCT05053126
Drug: oxycodone 20 mg
Normalized name: oxycodone 20 MG
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participant will receive an oral dose of oxycodone 20 mg
Study: NCT06472388
Drug: Everolimus 5 MG
Normalized name: everolimus 5 MG
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral everolimus 5 mg/daily
Study: NCT06504485
Drug: Bulevirtide
Normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: dose of 2 mg/day subcutaneously
Study: NCT04928495
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin C 500 mg / day for ten days
Study: NCT04928495
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine 1800 mg / day for ten days.
Study: NCT04928495
Drug: NAC + Bromhexine (BMX)
Normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC + Bromhexine (BMX) 32 mg / day for ten days.
Study: NCT05009030
Drug: COVID-19 vaccine
Normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung cancer patients will receive an anti-COVID19 vaccine approved by the European Medicines Agency according to the guidelines approved by the regulatory authorities
Study: NCT01017822
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04948463
Drug: Piperacillin and Tazobactam for Injection
Normalized name: Piperacillin and Tazobactam for Injection
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given if patient has no known allergies, until ANC recovery at 100mg/kg (max 4g) 6 hourly.
Study: NCT04948463
Drug: Cefepime Injection
Normalized name: cefepime Injection
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given if patient has non life-threatening hypersensitivity (preferred option), until ANC recovery at 50mg/kg (max 2g) 8 hourly.
Study: NCT04948463
Drug: Ceftazidime Injection
Normalized name: ceftazidime Injection
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If non life-threatening hypersensitivity (second option), given until ANC recovery at 50mg/kg (max 2g) 8 hourly
Study: NCT04948463
Drug: Vancomycin Injection
Normalized name: Vancomycin Injection
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If life-threatening hypersensitivity given with ciprofloxacin, given until ANC recovery at 15mg/kg (max 500mg) 6 hourly
Study: NCT04948463
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If life-threatening hypersensitivity given with vancomycin, given until ANC recovery at 10 mg/kg (max 400 mg) 12 hourly
Study: NCT04948463
Drug: Piperacillin and Tazobactam for Injection
Normalized name: Piperacillin and Tazobactam for Injection
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given if patient has no known allergies at 100mg/kg (max 4g) 6 hourly, stopping 48 hours post-fever resolution.
Study: NCT04948463
Drug: Cefepime Injection
Normalized name: cefepime Injection
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If non life-threatening hypersensitivity (preferred option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
Study: NCT04948463
Drug: Ceftazidime Injection
Normalized name: ceftazidime Injection
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If non life-threatening hypersensitivity (second option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
Study: NCT04948463
Drug: Vancomycin Injection
Normalized name: Vancomycin Injection
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If life-threatening hypersensitivity given with ciprofloxacin at 15mg/kg (max 500mg) 6 hourly, stopping 48 hours post-fever resolution
Study: NCT04948463
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If life-threatening hypersensitivity given with vancomycin at 10 mg/kg (max 400 mg) 12 hourly, stopping 48 hours post-fever resolution
Study: NCT04880850
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
Study: NCT04880850
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 26 weeks
Study: NCT04880850
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive subcutaneous (s.c.) injections of insulin aspart 2-4 times daily for 26 weeks
Study: NCT05425719
Drug: MB-102
Normalized name: MB-102 CD123 CAR
DrugBank: MB-102 CD123 CAR (DB17366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
Study: NCT00002017
Drug: Interleukin-2, Polyethylene Glycolated
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06300346
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron
Study: NCT04962503
Drug: Afamelanotide
Normalized name: Afamelanotide
DrugBank: Afamelanotide (DB04931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment.
Study: NCT05530278
Drug: Galicaftor
Normalized name: Galicaftor
DrugBank: Galicaftor (DB14894)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05530278
Drug: ABBV-576
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05530278
Drug: Navocaftor
Normalized name: Navocaftor
DrugBank: Navocaftor (DB19039)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05530278
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT05624918
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
Study: NCT05624918
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
Study: NCT04591210
Drug: Angiotensin II Receptor Blockers
Normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, and dose adjustments as appropriate.
Study: NCT06528015
Drug: probiotics combined with enteric-coated budesonide capsule
Normalized name: budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the 9-month treatment period, the following treatments will be received: probiotics combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics (each bag added active probiotic Lactobacillus casei Zhang ≥100 billion CFU) +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules.
Study: NCT06528015
Drug: probiotics placebo combined with enteric-coated budesonide capsules
Normalized name: budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the 9-month treatment period, the following treatments will be received: probiotics placebo combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics placebo +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules.